miR-137 and miR-501, both known to target GRIA1, have been proposed as potential AD biomarkers after decreased levels identification in serum [148,168], while miR-128 [159] and miR-191 [164] have been proposed as plasma-based biomarkers for AD with an AUC performance over 0.95. Here, GRIA1 is linked to Alzheimer disease.